drugset / Trial / NCT06466369
Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.
Timeline
- Start
- 2024-03-15
- Primary completion
- 2024-07-01
- Completion
- 2024-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tadalafil | Small molecule | 2.5 mg | — |
| Subject | Tadalafil | Small molecule | 5 mg | — |